SCHEMBL4658305

SCHEMBL4658305

Cc1ccccc1-c1cc(N2CCOCC2)nc2ccc([N+](=O)[O-])cc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
HPGD P15428 3/20 0.53
KDM4E B2RXH2 2/20 0.53
GAA P10253 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ACHE P22303 1/20 0.53
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 1/20 0.48
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
ATR Q13535 1/20 0.47
ATRIP Q8WXE1 1/20 0.47
MAPK1 P28482 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
USP2 O75604 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4659314 0.81 ALDH1A1 (0.58) ALDH1A1HPGDKDM4EGAASMN1; SMN2
SCHEMBL5653881 0.80 ALDH1A1 (0.56) ALDH1A1HPGDKDM4EGAASMN1; SMN2
SCHEMBL5654093 0.79 GBA1 (0.61) ALDH1A1HPGDKDM4EGAASMN1; SMN2
SCHEMBL4658288 0.79 ACHE (0.56) ALDH1A1HPGDACHEMEN1KMT2A
SCHEMBL4659313 0.77 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EGAASMN1; SMN2
SCHEMBL3559642 0.74 ALDH1A1 (0.72) ALDH1A1HPGDACHEMEN1KMT2A
SCHEMBL14349125 0.73 MCHR1 (0.49) ALDH1A1HPGDKDM4EGAASMN1; SMN2
SCHEMBL5910276 0.73 APP (0.60) ACHEKMT2AMAPTLMNA
SCHEMBL25269252 0.72 KMT2A (0.55) ALDH1A1HPGDGAASMN1; SMN2ACHE
SCHEMBL4659263 0.72 TACR1 (0.51) ALDH1A1HPGDKDM4EGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1819342-A4 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2008-12-17 EP disclosed
US-20070293492-A1 Quinoline Tachykinin Receptor Antagonists MERCK SHARP & DOHME CORP. 2007-12-20 US disclosed
EP-1819342-A1 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-08-22 EP disclosed
WO-2006060390-A1 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293492-A1 Quinoline Tachykinin Receptor Antagonists TACR1, TACR2, NPSR1 ALDH1A1 874/4885HPGD 1100/4885KDM4E 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.